MURA-7012
Understanding Our Treatment Candidates
Our enhanced IL-12 is engineered to leverage native IL-12’s anti-tumor potency while mitigating its hallmark toxicity.
The Challenge:
Native IL-12 is a highly potent pro-inflammatory cytokine that has a narrow therapeutic index when administered systemically.
Our Design:
To mitigate this toxicity, we split the IL-12p70 heterodimer into two inactive monomers: IL12p35 and IL-12p40. These individual subunits are then separately fused to antibody fragments and sequentially injected, which deliver and concentrate IL-12 preferentially in the tumor microenvironment to limit systemic exposure. In preclinical studies, MURA-7012 achieved the desired reduction in serum while maintaining tumor concentrations providing the potential to reduce systemic toxicities.
MURA-7012 is currently in preclinical development.
Visual Assets:
Infographic conveys the Fusion of IL-12 Subunits with Unique Tumor Antigen Antibodies
